Head-to-Head

Eli Lilly & Co. vs. Rigel Pharmaceuticals Inc. (New)

LLY

Eli Lilly & Co.

$1183.16 +0.25%

VS RIGL

Rigel Pharmaceuticals Inc. (New)

$42.45 -0.31%

Eli Lilly & Co. (LLY) comes out ahead, leading on 5 of 9 compared factors.

Size & Scale

LLYRIGL
Market Cap $1.05 trillion $795.39 million
Revenue (TTM) $79.67 billion $276.79 million
Net Income (TTM) $26.71 billion $321.91 million

LLY leads on 3 of 3 size & scale factors.

Valuation

LLYRIGL
P/E Ratio 39.72 2.51
Price / Book 31.05 1.87
Price / Sales 13.20 2.87

RIGL leads on 3 of 3 valuation factors.

Profitability

LLYRIGL
Net Margin 33.53% 116.30%
Return on Equity 78.84% 75.67%

LLY and RIGL split the profitability factors evenly.

Dividend

LLYRIGL
Dividend Yield 0.58% —
Payout Ratio 23.23 —

LLY and RIGL split the dividend factors evenly.

Risk & Sentiment

LLYRIGL
Short Interest 1.29% 42.81%

LLY leads on 1 of 1 risk & sentiment factors.

Dig deeper: LLY overview, LLY financials, RIGL overview, RIGL financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.